In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience Phase I full dataset demonstrates consistent dose related effects on the intensity and quality of the psychedelic experience LONDON, Feb. 22, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a neuroscience company focused on…


Previous articlePT295 – Sidarta Ribeiro – Dreams, LSD, and Biopiracy
Next articleTackling Trauma with Pharmahuasca and DMT